Use of mutated VEGF for antiangiogenic therapy

The invention relates to the application of oligonucleotide and polypeptide sequences of molecules belonging to the vascular permeability factor (VPF) family, their receptors and co-receptors and to their modifications in active immunotherapy against pathological entities whose course is associated...

Full description

Saved in:
Bibliographic Details
Main Authors FERNANDEZ MOLINA, LUIS, ENRIQUE, GAVILONDO COWLEY, JORGE, VICTOR, LOPEZ OCEJO, OMAR, BEQUET ROMERO, MONICA, SILVA RODRIGUEZ, RICARDO, DE LA CARIDAD, GALBAN RODRIGUEZ, ERNESTO, VAZQUEZ BLOMQUIST, DANIA, MARCIA, ACEVEDO CASTRO, BORIS, ERNESTO, MUSACHIO LASA, ALEXIS
Format Patent
LanguageEnglish
French
German
Published 08.06.2011
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The invention relates to the application of oligonucleotide and polypeptide sequences of molecules belonging to the vascular permeability factor (VPF) family, their receptors and co-receptors and to their modifications in active immunotherapy against pathological entities whose course is associated with an increase in vasculature. Said procedures can be used, inter alia, in monotherapy or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and infant retinopathy, rejection of transplanted organs, macular degeneration, neovascular glaucoma, hemangioma and angiofibroma.
Bibliography:Application Number: EP20030711811